{
  "success": true,
  "pagesUsed": [
    8,
    9,
    10,
    11,
    12,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel in patients with inoperable locally advanced or metastatic TNBC",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - Overall Survival",
        "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel as measured by Overall Survival",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - Patient Reported Outcomes",
        "text": "To evaluate the time to deterioration in Global Health Status",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Response",
        "text": "To evaluate Objective Response Rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - Duration of Response",
        "text": "To evaluate Duration of Objective Response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective - Clinical Benefit",
        "text": "To evaluate Clinical Benefit Rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Patient-Reported Outcomes Objective",
        "text": "To evaluate changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Quality of Life Objective",
        "text": "To evaluate changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Endpoint: Overall Survival",
        "text": "Overall Survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Endpoint: Time to deterioration in Global Health Status",
        "text": "Time to deterioration in Global Health Status",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint: Objective Response Rate",
        "text": "Objective Response Rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint: Duration of Objective Response",
        "text": "Duration of Objective Response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint: Clinical Benefit Rate",
        "text": "Clinical Benefit Rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint: Changes from Baseline in Patient Function and Symptoms",
        "text": "Changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Endpoint: Changes from Baseline in Overall Health and Quality of Life",
        "text": "Changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - PD-L1 Positive Subpopulation",
        "populationSummary": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation Summary measure: Hazard ratio from a stratified Cox regression model.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Missing tumor assessments",
            "text": "Patient missed two or more scheduled assessments immediately prior to the PFS event",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation",
        "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand - ITT Population",
        "populationSummary": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population) Summary measure: Hazard ratio from a stratified Cox regression model.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death from any cause during the study",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population)",
        "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Overall Survival",
        "populationSummary": "All randomised patients (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching",
            "text": "Patient receives subsequent anti-cancer therapy after progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "All randomised patients (ITT population)",
        "variableOfInterest": "Overall Survival",
        "summaryMeasure": "Hazard ratio"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 5,
      "exploratoryObjectives": 2,
      "totalEndpoints": 8,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel in patients with inoperable locally advanced or metastatic TNBC",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - Overall Survival",
        "text": "To evaluate the efficacy of atezolizumab plus paclitaxel compared with placebo plus paclitaxel as measured by Overall Survival",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - Patient Reported Outcomes",
        "text": "To evaluate the time to deterioration in Global Health Status",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Response",
        "text": "To evaluate Objective Response Rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - Duration of Response",
        "text": "To evaluate Duration of Objective Response",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective - Clinical Benefit",
        "text": "To evaluate Clinical Benefit Rate",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Exploratory Patient-Reported Outcomes Objective",
        "text": "To evaluate changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Quality of Life Objective",
        "text": "To evaluate changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Endpoint: Overall Survival",
        "text": "Overall Survival",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Endpoint: Time to deterioration in Global Health Status",
        "text": "Time to deterioration in Global Health Status",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_4",
        "name": "Secondary Endpoint: Objective Response Rate",
        "text": "Objective Response Rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Endpoint: Duration of Objective Response",
        "text": "Duration of Objective Response",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint: Clinical Benefit Rate",
        "text": "Clinical Benefit Rate",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint: Changes from Baseline in Patient Function and Symptoms",
        "text": "Changes from baseline in patient function and symptoms (EORTC QLQ C30 and QLQ BR23)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Endpoint: Changes from Baseline in Overall Health and Quality of Life",
        "text": "Changes from baseline in overall health and quality of life (EORTC QLQ C30, Items 29 and 30)",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - PD-L1 Positive Subpopulation",
        "populationSummary": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation Summary measure: Hazard ratio from a stratified Cox regression model.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Missing tumor assessments",
            "text": "Patient missed two or more scheduled assessments immediately prior to the PFS event",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "Adult patients with inoperable locally advanced or metastatic TNBC whose PD-L1 status is IC1/2/3 at the time of randomisation",
        "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand - ITT Population",
        "populationSummary": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population) Summary measure: Hazard ratio from a stratified Cox regression model.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of atezolizumab/placebo or paclitaxel due to toxicity or other reasons prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death from any cause during the study",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "All randomised patients with inoperable locally advanced or metastatic TNBC (Intent-to-Treat population)",
        "variableOfInterest": "Progression-free survival (PFS), defined as the time from randomisation to the first occurrence of disease progression (RECIST v1.1) or death from any cause",
        "summaryMeasure": "Hazard ratio from a stratified Cox regression model"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - Overall Survival",
        "populationSummary": "All randomised patients (ITT population) Summary measure: Hazard ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching",
            "text": "Patient receives subsequent anti-cancer therapy after progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Atezolizumab plus paclitaxel vs Placebo plus paclitaxel",
        "analysisPopulation": "All randomised patients (ITT population)",
        "variableOfInterest": "Overall Survival",
        "summaryMeasure": "Hazard ratio"
      }
    ]
  }
}